锌补充对 2 型糖尿病患者血清脂联素浓度和血糖控制的影响。
Effects of zinc supplementation on serum adiponectin concentration and glycemic control in patients with type 2 diabetes.
机构信息
Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran; Cardiac Primary Prevention Research Center (CPPRC), Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran; Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia.
出版信息
J Trace Elem Med Biol. 2019 Sep;55:20-25. doi: 10.1016/j.jtemb.2019.05.007. Epub 2019 May 14.
BACKGROUND
Previous studies have suggested that zinc is involved in insulin homeostasis. Adiponectin is a well-known adipokine with anti-diabetic, anti-atherogenic, and anti-inflammatory properties. The aim of this study was to investigate the effect of zinc supplementation on glycemic control, and the potential mediating role of adiponectin, in patients with type 2 diabetes.
METHODS
In this randomized double-blind placebo-controlled clinical trial, 60 patients with diabetes, 30-60 years, were randomized to receive either 30 mg/d zinc (as zinc gluconate) or placebo for 12 weeks. Circulating levels of adiponectin, zinc, glucose homeostasis parameters, and lipid profiles, as well as anthropometric parameters and dietary intakes, were assessed.
RESULTS
About 53.3% of the patients had zinc insufficiency at baseline. Serum zinc levels improved significantly in the intervention than control group following 12 weeks supplementation (P < 0.001). Adiponectin (1.23 ± 2.23 μg/ml, P = 0.006) and insulin (3.6 ± 4.66 μIU/ml, P = 0.001) levels increased significantly compared to baseline in the zinc group; but this change was not significant compared with the control group. Following supplementation, there were no significant differences in glycemic control and anthropometric parameters between the two groups. Serum HDL levels increased significantly in the zinc (5.37 ± 14.8 mg/dl) compared to control (-1.53 ± 6.9 mg/dl) group following supplementation (P = 0.039).
CONCLUSION
Despite a significant increase in serum zinc level, no improvement was observed in glycemic control, following 12 weeks supplementation with 30 mg/d zinc (as zinc gluconate). Zinc supplementation restored adiponectin concentrations partly within the intervention group, and increased HDL levels compared to the control group. The current findings did not support improvement in glucose homeostasis following zinc supplementation in patients with type 2 diabetes under the present study design.
背景
先前的研究表明，锌参与胰岛素稳态。脂联素是一种具有抗糖尿病、抗动脉粥样硬化和抗炎特性的知名脂肪因子。本研究旨在探讨补锌对 2 型糖尿病患者血糖控制的影响，以及脂联素的潜在介导作用。
方法
在这项随机、双盲、安慰剂对照的临床试验中，将 60 名年龄在 30-60 岁之间的糖尿病患者随机分为两组，分别接受 30mg/d 锌（葡萄糖酸锌）或安慰剂治疗 12 周。评估循环脂联素、锌、葡萄糖稳态参数和血脂谱以及人体测量参数和饮食摄入量。
结果
约 53.3%的患者在基线时有锌不足。与对照组相比，干预组在补充 12 周后血清锌水平显著改善（P<0.001）。与基线相比，锌组的脂联素（1.23±2.23μg/ml，P=0.006）和胰岛素（3.6±4.66μIU/ml，P=0.001）水平显著升高；但与对照组相比，这一变化并不显著。补充后，两组间血糖控制和人体测量参数无显著差异。与对照组相比，补充后锌组（5.37±14.8mg/dl）血清高密度脂蛋白水平显著升高（P=0.039）。
结论
尽管血清锌水平显著升高，但在接受 30mg/d 葡萄糖酸锌补充 12 周后，血糖控制并未得到改善。锌补充部分恢复了干预组的脂联素浓度，并使高密度脂蛋白水平高于对照组。根据本研究设计，补锌并未改善 2 型糖尿病患者的葡萄糖稳态。
Zotero 插件